Maravai LifeSciences Holdings - MRVI EV/Sales Multiple

Public company logo of Maravai LifeSciences Holdings (MRVI)

The current price-to-sales ratio of Maravai LifeSciences (MRVI) correlates with the company's transition to eco-friendly reagents and green chemistry principles. The value of 9941.69 shows the latest metric reading, while the business relies on the automation of nucleic acid synthesis for vaccine development. Revenue stability is driven by CleanCap technology, which creates high switching costs for biopharmaceutical clients.

Maravai LifeSciences Corp (MRVI) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Maravai LifeSciences Corp (MRVI)

- money and cash flow information:
Initial company analysis:Maravai LifeSciences - MRVI
Original product of Maravai LifeSciences Holdings

This indicator determines the market value of the business relative to sales volume, excluding the impact of debt load. The metric allows for an assessment of revenue generation efficiency without distortions caused by capital structure. By analyzing historical EV/Sales trends, an investor can identify whether an asset is overbought or possesses growth potential. For Maravai LifeSciences (MRVI), the stability of this ratio is supported by a robust audit of reagent suppliers. This ensures the continuity of medical analysis production and the predictability of cash flows.

Competitor analysis for Maravai LifeSciences

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue